Real‐World Evidence of Long‐Term Dulaglutide Use: Sustained Glycemic and Weight Improvements Beyond Three Years
Authors' conclusion
Dulaglutide provided durable improvements in glycemic control and weight reduction for more than 3 years, even in patients with long-standing T2DM and comorbidities. These results support its role as a long-term treatment option in real-world clinical practice.
Study context
- Population
- Patients with T2D treated continuously with weekly dulaglutide for ≥3 years, 2016–2023, single tertiary hospital; mean age 60.0 years, mean diabetes duration 17.4 years
- Participants
- 403 patients
- Exposure
- Long-term dulaglutide: baseline vs follow-up
- Dulaglutiden = 403
- Outcome
- Sustained glycemic and weight-lowering effects (HbA1c, fasting plasma glucose (FPG), body weight)
- Follow-up
- Mean 4.3 years
Methodological detailssingle tertiary hospital
- Single tertiary hospital
Main finding
As reported in the abstract
HbA1c
Mean HbA1c reduction (p < 0.001)
1.1%
12 mmol/mol
Body weight decrease (p < 0.001)
2.9 kg
Observational data: associations, not effects.
Further findings
- Baseline HbA1c was the strongest predictor of glycemic improvement
Original publication
Real‐World Evidence of Long‐Term Dulaglutide Use: Sustained Glycemic and Weight Improvements Beyond Three Years. Clin Endocrinol (Oxf). Published 12 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →